Tenaya Therapeutics, Inc. (TNYA)

Over the past six months, Tenaya Therapeutics completed enrollment in cohorts of its MyPEAK-1 and RIDGE-1 trials, with positive safety reviews allowing for dose escalation and expansion. The company reported Q3 2025 financial results, showing a narrowed net loss and reduced expenses, and presented positive interim data for TN-201, but the MyPEAK-1 trial was placed on a clinical hold, which was later resolved. Tenaya Therapeutics announced the pricing of a public offering and provided an update on its clinical development programs, aiming to build on the positive TN-201 results and report data from the RIDGE-1 study. The company raised $60 million in Q4 2025, extending its cash runway through mid-2027. The stock price experienced an 18.34% decline between February 5, 2025, and February 4, 2026, decreased by 12.90% over the last 12 months, but increased by 24.47% in the month leading up to February 6, 2026.

As a clinical-stage biotechnology company, Tenaya Therapeutics, Inc. does not currently generate revenue from commercial product sales, and therefore, there is no traditional demand seasonality for its products or services. The company's focus is on the long and capital-intensive process of research, development, and clinical trials.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease, operating within the Healthcare sector and Biotechnology & Medical Research industry. The company employs a multi-platform approach, focusing on gene therapy, cellular regeneration, and precision medicine to address the underlying genetic causes of heart conditions. Its major product candidates include TN-201, an AAV9-based gene therapy in Phase 2 clinical trials for MYBPC3-associated HCM; TN-401, an AAV9-based gene therapy in Phase 1 clinical trials for PKP2-associated ARVC; and TN-301, a small molecule HDAC6 inhibitor in Phase 1 clinical trials for HFpEF. The company also has early-stage preclinical programs targeting both rare genetic disorders and more prevalent heart conditions.

Tenaya Therapeutics, Inc. is headquartered in South San Francisco, California. Its clinical development efforts, such as the MyClimb natural history study for pediatric HCM, have a broader reach, enrolling patients at 29 sites worldwide.

Tenaya Therapeutics' brand reputation has been shaped by its scientific advancements and progress in clinical trials. The presentation of positive interim data for TN-201 and the rapid resolution of the clinical hold for the MyPEAK-1 trial contributed positively to its reputation. The company's mission to discover and deliver curative therapies for heart disease, coupled with its core values, underpins a reputation focused on addressing critical unmet medical needs. Its reputation is intrinsically linked to the success and safety of its ongoing clinical programs.

Tenaya Therapeutics, Inc. has a diverse ownership structure. Insiders hold a significant portion of the company's stock, estimated at approximately 48.65% to 54.76%. Institutional investors hold around 11.97% to 22.67% of the shares, with major holders including The Column Group LLC, Vanguard Group Inc, Millennium Management LLC, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Renaissance Technologies Llc, Geode Capital Management, Llc, Euclidean Capital LLC, and Alphabet Inc. The remaining shares are held by retail and public investors.